- Previous Close
0.061 - Open
0.061 - Bid 0.061 x --
- Ask 0.062 x --
- Day's Range
0.061 - 0.063 - 52 Week Range
0.046 - 0.098 - Volume
2,500,000 - Avg. Volume
2,296,098 - Market Cap (intraday)
370.216M - Beta (5Y Monthly) -0.14
- PE Ratio (TTM)
3.10 - EPS (TTM)
0.020 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 22, 2007
- 1y Target Est
--
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agent for the treatment of Type 2 diabetes. In addition, the company is involved in the distribution of hydrogel wound dressing for post-skin injury and minimally invasive surgery wound healing. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
www.uni-bioscience.comRecent News: 0690.HK
View MorePerformance Overview: 0690.HK
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0690.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0690.HK
View MoreValuation Measures
Market Cap
370.22M
Enterprise Value
296.97M
Trailing P/E
3.92
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.76
Price/Book (mrq)
1.18
Enterprise Value/Revenue
0.58
Enterprise Value/EBITDA
2.84
Financial Highlights
Profitability and Income Statement
Profit Margin
19.44%
Return on Assets (ttm)
17.05%
Return on Equity (ttm)
36.79%
Revenue (ttm)
508.4M
Net Income Avi to Common (ttm)
98.86M
Diluted EPS (ttm)
0.020
Balance Sheet and Cash Flow
Total Cash (mrq)
179M
Total Debt/Equity (mrq)
29.42%
Levered Free Cash Flow (ttm)
16.7M